Presentation to Focus on Clinical Experience in Patients Using CTD's Developmental Drug Trappsol(R) Cyclo(TM)
ALACHUA, FL -- (Marketwired) -- 05/03/16 -- CTD Holdings (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it will present its findings on the intravenous treatment of Niemann-Pick Type C (NPC) patients at the annual conference of the Ara Parseghian Medical Research Foundation in Tucson, Arizona, June 4-7, 2016.
CTD and physician scientists from the US and Brazil co-authored the accepted paper, which will present case studies from nine patients using CTD's drug candidate Trappsol® Cyclo™ -- a proprietary hydroxylpropyl-beta cyclodextrin (HPBCD) -- on a compassionate basis and administered intravenously to treat the rare and fatal NPC disease, and two patients who used HPBCD from other sources.
NPC is characterized by cholesterol accumulation in all cells of the body. It leads to cognitive impairment, movement disorders, and liver and lung dysfunction, among other systemic challenges, and is ultimately fatal. CTD believes that the collective data from the study support the safety and benefit of systemic intravenous administration of Trappsol® Cyclo™ and provide a foundation for formal clinical studies supported by the company to advance Trappsol® Cyclo™ in market approval.
CTD's presentation will be given by Dr. Caroline Hastings and Dr. Sharon Hrynkow, the company's Senior Vice President for Medical Affairs. Dr. Hastings, a pediatric oncologist at the UCSF Benioff Children's Hospital Oakland, was the first physician in the United States to use HPBCD in the form of Trappsol® Cyclo™ to treat NPC. Dr. Hastings is also a member of CTD's Scientific Advisory Board and Co-Chair, with Dr. Hrynkow, of CTD's Family and Physician Listening Circle. Dr. Hrynkow is also Co-Chair of the Scientific Advisory Board.
In addition to Dr. Hastings and Dr. Hrynkow, other co-authors of the study are Dr. Benny Liu, gastroenterologist at the Alameda Health System Oakland and the first scientist to show efficacy of HPBCD in a NPC animal model, and other physicians from the United States and Brazil who have used Trappsol® Cyclo™ or other forms of HPBCD to treat NPC patients for one to five years. They are Dr. Camillo Vieira of the Universidad Federal da Bahia, Salvador, Brazil; Dr. Charles Lourenco and Dr. Marcela Almeida of the Universidade de Sao Paolo, Sao Paolo, Brazil; Dr. Diane Williams, Ashland, Oregon; Dr. Ellen Plummer of Asante Rogue Regional Medical Center, Medford, Oregon; Dr. Raymond Wang, Children's Hospital, Orange County, California; Dr. Alicia Casey and Dr. Olaf Bodamer of Boston Children's Hospital, Boston, Massachusetts; and Dr. Cyrus Bascon, Children's Hospital and Research Center, Oakland, California.
"We are pleased that the community of physicians and scientists who have used Trappsol® Cyclo™ on a compassionate basis have come together to analyze safety and clinical outcome measures," said N. Scott Fine, CTD Chairman of the Board and CEO. "We look forward to sharing with the community what has been learned from more than five years' experience with intravenous administration of cyclodextrins in the treatment of NPC."
The Ara Parseghian Medical Research Foundation Annual Conference brings together top researchers in the Niemann-Pick field along with families, caregivers and advocates to consider new strategies to treat and potentially cure Niemann-Pick disease.
About the Company:
CTD Holdings, Inc. is a biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company's Trappsol® Cyclo™, an orphan drug designated product in the United States and the EU, is used to treat Niemann-Pick Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company's website: www.ctd-holdings.com
Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Source: CTD Holdings, Inc.